Wang et al.31
|
2018 |
BALB/c athymic nude mice |
female |
30 |
BT474 (107) cells inoculated into mammary fat pad |
human HER-2+ |
Zhou et al.32
|
2021 |
BALB/c athymic nude mice |
female |
NR |
MDA-MB-231-D3H2LN cells (2 × 106) and 1 × 106 of stimulated PBMCs injected subcutaneously into mammary fat pads |
human triple negative |
Zhao et al.33
|
2020 |
BALB/c mice |
female |
24 |
4T1 cells (1.0 × 106 cells) injected into the mammary fat pad |
murine triple negative |
Xie et al.34
|
2021 |
BALB/c nude mice |
female |
20 |
MDA-MB-231 cells (2 × 106) were mammary implanted in the mice |
human triple negative |
Wang et al.35
|
2019 |
BALB/c mice |
female |
40 |
mice were injected with 1 × 106 of 4T1 cells into their flanks |
murine triple negative |
Tian et al.36
|
2020 |
BALB/c mice |
female |
25 |
1 × 105 of 4T1 cells were implanted in mice |
murine triple negative |
Si et al.37
|
2022 |
BALB/cJ mice |
female |
40 |
1 × 106 of 4T1-FLuc cells were injected into the mammary fat pad |
murine triple negative |
NSG mice |
female |
NR |
NSG mice were injected subcutaneously into their right flanks by fresh harvested tumor or fresh frozen tumor tissues minced into small fragments |
murine triple negative |
Pi et al.38
|
2018 |
athymic nu/nu outbred mice |
female |
15 |
2 × 106 of MDA-MB-468 cells for orthotopic mammary fat-pad xenograft tumor |
human triple negative |
Peng et al.39
|
2022 |
BALB/c mice |
female |
18 |
mice were injected with 1.25 × 105 of 4T1 cells in the mammary fat pad |
murine triple negative |
NSG-SGM3 mice |
female |
18 |
mice were injected with 1 × 106 of Ca1 cells into the mammary fat pad |
human triple negative |
BALB/c nude mice |
female |
12 |
the nude mice were injected with 5 × 106 of MDA-MB-468 cells into the mammary fat pad |
human triple negative |
BALB/c mice |
female |
20 |
mice were injected intravenously with 2.5 × 105 of 4T1-hEGFR cells |
murine triple negative |
O’Brien et al.40
|
2018 |
BALB/c athymic nude mice |
female |
32 |
mice received an injection of 1 × 107 HCC-luc cells into the inguinal mammary fat pad |
human HER-2+ |
Naseri et al.41
|
2018 |
BALB/c mice |
female |
40 |
1 × 106 cells of 4T1 or TUBO tumor cells were inoculated subcutaneously in the flank region of mice |
murine triple negative and HER-2+ |
Martins-Marques et al.42
|
2016 |
Swiss nude mice |
female |
NR |
0.5 × 106 of 4T1 cells in opposite flanks of female mice were injected subcutaneously |
murine triple negative |
Li et al.43
|
2020 |
BALB/c nude mice |
female |
20 |
1 × 106 of MDA-MB-231 cells per pad were injected in right mammary pad for orthotopic tumor model |
human triple negative |
Jung et al.44
|
2018 |
BALB/c nu/nu mice |
female |
NR |
1 × 106 of MDA-MB-231 were injected subcutaneously into the right flaks of mice |
human triple negative |
Haney et al.45
|
2020 |
BALB/c mice |
female |
42 |
0.8 × 106 of 8FlmC-FLuc-T11 cells/mouse for orthotopic tumor model |
murine triple negative |
athymic nu/nu mice |
female |
42 |
0.1 × 106 of MDA-MB-231 cells were injected to left side mammary fat pad mice |
human triple negative |
Hadla et al.46
|
2016 |
nude mice |
female |
NR |
3 × 106 of MDA-MB-231 cells were injected subcutaneously into mice |
human triple negative |
Gong et al.47
|
2019 |
BALB/c nude mice |
male |
40 |
1 × 107 cells of MDA-MB-231 cell suspension was injected into right flank of male mice |
human triple negative |
Gomari et al.48
|
2019 |
B6 nude mice |
female |
16 |
mouse was injected subcutaneously in flank with 1 × 106 of TUBO cells |
murine HER-2+ |
Feng et al.49
|
2021 |
BALB/c mice |
female |
16 |
1 × 106 of 4T1-luc cells were injected into the mammary gland of mice |
murine triple negative BC |
Cheng et al.50
|
2022 |
NSG mice |
female |
20 |
mice have a subcutaneous injection in the right hind limbs with 5 × 106 of BT-20 cells and they received intraperitoneal injection of human PBMCs (20 × 106 cells per mouse) |
human triple negative |
Nguyen Cao et al.51
|
2022 |
BALB/c nude mice |
female |
20 |
mice have a subcutaneous injection with 1 × 106 of MCF-7 cells into the right back region |
human luminal-A |
Ahmed et al.52
|
2015 |
BALB/c mice |
female |
24 |
mice have a subcutaneous injection with 1 × 107 4T1 cells into their mammary fat pads |
murine triple negative |
Hong et al.53
|
2019 |
BALB/c mice |
female |
18 |
mice were orthotopically inoculated with 1 × 106 of 4T1 cells into the mammary fat pad |
murine triple negative |
Liu et al.54
|
2019 |
BALB/c mice |
female |
60 |
mice were subcutaneously injected at the right flanks with 1 × 106 of 4T1 cells |
murine triple negative |
Melzer et al.55
|
2019 |
NOD SCID mice |
female |
12 |
2 × 106 of MDA-hyb1 cells were injected subcutaneously into female NOD SCID mice |
human triple negative |
Shi et al.56
|
2020 |
NSG mice |
female |
10 |
1.5 × 106 of HCC 1954 cells were subcutaneously implanted into the right flank of NSG mice then 2 i.p. injections of 20 × 106 activated human PBMCs) with a 9-day interval |
human HER-2+ |
Usman et al.57
|
2018 |
nude mice |
female |
32 |
5 × 106 of CA1a cells were injected subcutaneously in the left and right flanks of female nude mice |
human triple negative |
Wan et al.58
|
2018 |
BALB/c mice |
female |
36 |
2 × 106 of MDA-MB-231 were inoculated subcutaneously to the flanks of BALB/c mice |
human triple negative |
Wang et al.59
|
2017 |
BALB/c mice |
female |
42 |
3.0 × 106 of MDA-MB-231 cells were injected subcutaneously into the right flanks of the mice |
human triple negative |
Xiong et al.60
|
2019 |
BALB/c mice |
female |
30 |
1 × 106 of 4T1 cells were injected into the mammary fat pad of mice |
murine triple negative |